WCN25-1523 CIRCULATING ACE2 ACTIVITY IS INCREASED IN DIAGNOSED COVID-19 PATIENTS

Methods: A hospital based observational study was conducted among patients on MHD who developed confirmed COVID-19 from January 2020 to August 2024.Data were collected by using standardized forms and analysis was done.Results: The over-all trend of prevalence of COVID-19 among maintenance HD was falling.The prevalence was 'zero' (0/81) in March 2020 First wave (wild type).In August 2020, Second wave (Alpha wave plus wild type), the prevalence was 22.2% (18/81); it rose to 52% (51/98) in July 2021 Third wave (Delta).Then, it dropped to 44% (33/75) in January 2022 Fourth wave (Omicron); and , it decreased to 39.5% (30/ 76) in December 2022 Fifth wave (Omicron Variant).It became half 14.3% (15/105) in 2023.In 2024 (till end of August) the prevalence was 3.6% (4/112).The number of severe cases were down trend over 5 years.In Second wave (Alpha wave plus wild type), half of the cases (9/ 18) were severe according to WHO classification and they required hospitalization; the death rate was 33.3% (6/18).In Third wave (Delta), nearly 30% (15/51) of them required oxygen and mortality rate was nearly 10% (5/51).In Fourth wave (Omicron), the percentage of severe cases dropped dramatically to 3% (1/33) and mortality rate was 3%(1/ 33).The figure remained stable in Fifth wave (Omicron Variant).In 2023, one case expired from septicemia following mild COVID-19.In 2024 (till end of August), none of the infected cases were severe and the survival rate was 100%.They received total 6 doses of vaccine till 2024; first dose of SARS-CoV-2 vaccine (Covishield) was given after second wave; second dose of SARSCoV2 vaccine (Covishield) was repeated after third wave; third and fourth doses of SARS-CoV-2 vaccine (Covaxin) were given after fourth wave; Sinopharm vaccine was given in July 2023; and, Pfiza vaccine was given in 2024.